Pictured: Eli Lilly's office in Indianapolis/iStock, jetcityimage

图片：礼来公司在印第安纳波利斯/伊斯托克的办公室

Full results from the Phase III SURMOUNT-3 trial showed that Eli Lilly’s tirzepatide induces strong and long-lasting weight loss when given after an intensive lifestyle intervention program, the company announced Sunday.

该公司周日宣布，III期CONTROVER-3试验的全部结果显示，礼来公司的tirzepatide在强化生活方式干预计划后给予强烈而持久的体重减轻。

SURMOUNT-3, a randomized, double-blinded, placebo-controlled and parallel trial, enrolled 806 overweight or obese adults who had weight-related comorbidities, excluding type 2 diabetes. All participants underwent a 12-week intensive lifestyle adjustment program, after which those who lost at least 5% of their body weight continued on to receive tirzepatide or placebo..

COMPERATE-3是一项随机，双盲，安慰剂对照和平行试验，招募了806名超重或肥胖成人，他们患有与体重相关的合并症，不包括2型糖尿病。所有参与者都接受了为期12周的强化生活方式调整计划，之后那些体重减轻至少5%的人继续接受替西帕肽或安慰剂。。

At the 72-week follow-up, participants in the tirzepatide group saw a 21.1% mean weight loss, whereas placebo counterparts gained 3.3% bodyweight on average. Over the entire 84-week study period— including the 12-week lifestyle intervention lead-in—tirzepatide-treated participants achieved a 26.6% total mean weight loss, as opposed to only 3.8% in the placebo arm..

在72周的随访中，tirzepatide组的参与者平均体重减轻21.1%，而安慰剂组平均体重增加3.3%。在整个84周的研究期间-包括替泽帕肽治疗参与者的12周生活方式干预导致平均体重减轻26.6%，而安慰剂组仅为3.8%。。

The results were published Sunday in the journal Nature Medicine and were presented by Lilly over the weekend during The Obesity Society’s ObesityWeek 2023, held in Dallas, Texas.

结果星期日在“自然医学”杂志上发表，并由礼来公司在周末在德克萨斯州达拉斯举行的肥胖协会肥胖症周2023年期间发表。

“While intensive lifestyle intervention is an important part of obesity management, these results underscore the difficulty some people face maintaining weight loss with diet and exercise alone,” Jeff Emmick, senior vice president of product development at Lilly, said in a statement. Adding tirzepatide to an intensive lifestyle regimen could lead to “greater, longer-lasting weight reduction,” he added..

礼来公司产品开发高级副总裁杰夫·埃米克（Jeff Emmick）在一份声明中说：“虽然密集的生活方式干预是肥胖管理的重要组成部分，但这些结果强调了一些人仅靠饮食和运动维持体重减轻的困难。他补充说，在强化的生活方式中加入替泽帕肽可能会导致“更大，更持久的减肥”。。

Tirzepatide’s safety profile in SURMOUNT-3 was consistent with what had previously been reported. The most common side effects were gastrointestinal toxicities, such as nausea, diarrhea and constipation, which were generally mild to moderate in severity.

Tirzepatide在ONVERATE-3中的安全性与先前报道的一致。最常见的副作用是胃肠道毒性，例如恶心，腹泻和便秘，其严重程度通常为轻度至中度。

Around 10% of patients taking tirzepatide dropped out of the study due to adverse events, while only 2.1% of placebo comparators did so.

约有10%服用tirzepatide的患者由于不良事件而退出研究，而只有2.1%的安慰剂对照者这样做。

Tirzepatide is a peptide therapeutic that works by targeting and activating both the GIP and GLP-1 receptors, which are found in the area of the brain responsible for appetite regulation. It won the FDA’s approval in May 2022 for the treatment of type 2 diabetes, for which tirzepatide is being marketed under the brand name Mounjaro..

Tirzepatide是一种肽治疗剂，通过靶向和激活GIP和GLP-1受体起作用，GIP和GLP-1受体存在于负责食欲调节的大脑区域。它于2022年5月获得FDA批准用于治疗2型糖尿病，其中tirzepatide以商品名Mounjaro销售。。

Lilly is also developing tirzepatide as a weight-loss treatment, for which the company’s rolling submission to the FDA is currently ongoing, according to its website. In October 2022, the FDA granted tirzepatide its Fast Track designation in this indication.

根据其网站，礼来公司还在开发tirzepatide作为减肥治疗药物，目前该公司正在向FDA提交滚动提交。2022年10月，FDA在本适应症中授予tirzepatide快速通道名称。

Joining tirzepatide in Lilly’s weight-loss arsenal is orforglipron, an investigational oral non-peptide agonist of the GLP-1 receptor. In June 2023, the company posted mid-stage data demonstrating that the candidate can cut 8.6% to 12.6% of participants’ body weight after 26 weeks.

加入礼来公司减肥武库中的tirzepatide是orforglipron，一种GLP-1受体的研究性口服非肽激动剂。2023年6月，该公司发布中期数据，证明候选人在26周后可以减少参与者体重的8.6%至12.6%。

In July 2023, Lilly dropped $1.93 billion to acquire Versanis and its weight-loss monoclonal antibody bimagrumab.

2023年7月，礼来下降了19.3亿美元，收购了Versanis及其减肥单克隆抗体bimagrumab。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. He can be reached at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Tristan Manalac是位于菲律宾大马尼拉的独立科学作家。他可以联系到tristan@tristanmanalac.com或者tristan.manalac@biospace.com.